HUYA Bioscience Int’l Announces Collaboration Agreement With The Beijing Institute Of Materia Medica, Chinese Academy Of Medical Sciences And Peking Union Medical College

HUYA to Collaborate on Pre-clinical and Clinical Studies for Chinese Drugs

San Diego, CA – February 18, 2009 — HUYA Bioscience International, the leader in US/China pharmaceutical co-development, today announced a partnership agreement with the Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College (collectively – The Beijing Institute of Materia Medica, BIMM). The agreement grants HUYA the opportunity to collaborate with BIMM on pre-clinical safety and efficacy, and clinical trial protocols. The agreement also provides HUYA with the right of first review and negotiation for the licensing and development of certain new compounds owned or controlled by BIMM. This right includes drugs in discovery and development for use in the areas of cardiology, endocrinology, oncology, immunology, hematology, neuroscience and anti-infectives. Read more